JP2015502363A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502363A5
JP2015502363A5 JP2014547275A JP2014547275A JP2015502363A5 JP 2015502363 A5 JP2015502363 A5 JP 2015502363A5 JP 2014547275 A JP2014547275 A JP 2014547275A JP 2014547275 A JP2014547275 A JP 2014547275A JP 2015502363 A5 JP2015502363 A5 JP 2015502363A5
Authority
JP
Japan
Prior art keywords
tsh
composition
peg
cysteine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502363A (ja
JP6255348B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/067705 external-priority patent/WO2013095905A1/en
Publication of JP2015502363A publication Critical patent/JP2015502363A/ja
Publication of JP2015502363A5 publication Critical patent/JP2015502363A5/ja
Application granted granted Critical
Publication of JP6255348B2 publication Critical patent/JP6255348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547275A 2011-12-19 2012-12-04 甲状腺刺激ホルモン組成物 Active JP6255348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577412P 2011-12-19 2011-12-19
US61/577,412 2011-12-19
PCT/US2012/067705 WO2013095905A1 (en) 2011-12-19 2012-12-04 Thyroid stimulating hormone compositions

Publications (3)

Publication Number Publication Date
JP2015502363A JP2015502363A (ja) 2015-01-22
JP2015502363A5 true JP2015502363A5 (enExample) 2016-01-21
JP6255348B2 JP6255348B2 (ja) 2017-12-27

Family

ID=47520247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547275A Active JP6255348B2 (ja) 2011-12-19 2012-12-04 甲状腺刺激ホルモン組成物

Country Status (7)

Country Link
US (4) US20140357846A1 (enExample)
EP (1) EP2793948B1 (enExample)
JP (1) JP6255348B2 (enExample)
KR (1) KR102071731B1 (enExample)
CN (1) CN104220097B (enExample)
BR (1) BR112014014868B1 (enExample)
WO (1) WO2013095905A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687270B1 (ko) 2013-10-29 2016-12-19 한국 한의학 연구원 상륙 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물
KR101794289B1 (ko) * 2015-11-05 2017-11-06 주식회사 프로젠 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 정제 방법
MA45473A (fr) * 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0228604A3 (en) 1985-12-11 1988-10-12 Sloan-Kettering Institute For Cancer Research Isolation of a gene encoding human thyrotropin beta subunit
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
AU2003279750A1 (en) * 2002-06-28 2004-01-19 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US7267941B2 (en) * 2002-12-19 2007-09-11 The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health Cyanovirin variant-polymer conjugates
EP1706138A2 (en) * 2003-12-05 2006-10-04 ZymoGenetics, Inc. Methods for treating inflammation using thyroid stimulating hormone
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
EP2049661A4 (en) * 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
DK2063909T3 (da) * 2006-09-19 2013-01-02 Genzyme Corp Formuleringer til terapeutisk administration af thyroid-stimuleringshormon (TSH)
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
WO2011143274A1 (en) * 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
IT1404011B1 (it) * 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Similar Documents

Publication Publication Date Title
ES2380107T3 (es) Combinación de inmunogenoterapia y quimioterapia para el tratamiento del cáncer y enfermedades hiperproliferativas
TWI405581B (zh) 蛋白質或胜肽持續釋放給藥之組合物
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
HRP20221021T1 (hr) T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02
JP2017523184A5 (enExample)
JP2006523437A5 (enExample)
JP2017502047A5 (enExample)
JP2014526254A5 (enExample)
JP2014521684A5 (enExample)
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
ES2690147T3 (es) Apelina pegilada y usos de la misma
JP2011518179A5 (enExample)
JP2012067116A5 (enExample)
JP2021505661A5 (enExample)
JP2010505444A5 (enExample)
RU2015143057A (ru) Гипергликозилированные связывающие полипептиды
JP2010515686A5 (enExample)
NZ602824A (en) Sparc binding peptides and uses thereof
RU2010114043A (ru) Применение бета-меланотропина в качестве терапевтического средства, например, для лечения спид или болезни альцгеймера
RU2010137743A (ru) Конъюгированные молекулы фактора viii
RU2011100801A (ru) Конъюгаты для введения биологически активных соединений
US11707610B2 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
RU2010114015A (ru) Применение пептида в качестве терапевтического средства
JP2012067099A5 (enExample)
CN104144697A (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物